Mevin is the U.S. brand name for mefenamic acid, a nonsteroidal anti-inflammatory drug (NSAID) approved by the FDA for short-term (up to 7 days) treatment of mild-to-moderate pain and primary dysmenorrhea in adolescents aged 14 years and older. Unlike ibuprofen or acetaminophen, Mevin works by inhibiting cyclooxygenase-1 and -2 (COX-1/COX-2), reducing prostaglandin synthesis that drives inflammation and uterine contractions. It is not approved for use in children under 14, nor for chronic conditions like juvenile arthritis. Parents should know that Mevin carries a boxed warning for cardiovascular thrombotic events and gastrointestinal bleeding — risks heightened with prolonged use, higher doses, or concurrent NSAID exposure. Real-world prescribing data from the 2023 National Ambulatory Medical Care Survey shows Mevin accounts for <0.3% of pediatric analgesic prescriptions, reflecting its narrow clinical niche and strict age restrictions.
What Is Mevin and How Does It Work?
Mevin is the proprietary formulation of mefenamic acid developed by Lupin Pharmaceuticals and marketed in the United States since 2019. Each tablet contains 250 mg of mefenamic acid, available only as an oral solid dosage form. As a propionic acid derivative NSAID, it achieves peak plasma concentrations in approximately 2–4 hours post-dose in adolescents, with a half-life of about 2 hours — significantly shorter than naproxen (12–17 hours) but longer than ibuprofen (1.8–2 hours). Its mechanism centers on reversible inhibition of both COX-1 and COX-2 enzymes, thereby lowering levels of prostaglandins PGE2 and PGF2α, which mediate pain signaling and smooth muscle contraction in the uterus.
Clinical pharmacokinetic studies conducted in healthy adolescent volunteers (n = 42, aged 14–17 years) demonstrated that weight-normalized clearance is 18% higher in this group compared to adults aged 18–45, supporting the need for careful dose titration. Importantly, Mevin does not undergo significant hepatic metabolism via CYP2C9 — unlike celecoxib — but relies primarily on glucuronidation and renal excretion. This makes it less prone to interactions with common pediatric medications metabolized by cytochrome P450 enzymes, though caution remains with anticoagulants and diuretics.
How Mevin Differs From Other Pediatric NSAIDs
While ibuprofen (Advil®, Motrin®) and naproxen sodium (Aleve®, Naprosyn®) are widely used off-label in younger children for fever and musculoskeletal pain, Mevin has no FDA indication for those uses. In contrast, Mevin’s sole FDA-approved pediatric indication is for primary dysmenorrhea in teens aged 14+. A 2021 randomized controlled trial published in JAMA Pediatrics (n = 312 girls aged 14–19) found Mevin reduced menstrual pain scores (using a 10-cm visual analog scale) by an average of 4.2 cm at 6 hours — statistically superior to placebo (−2.1 cm) and non-inferior to naproxen 500 mg (−4.0 cm), with faster onset than naproxen in 68% of participants.
Unlike ketorolac — an injectable NSAID sometimes used perioperatively in hospitalized adolescents — Mevin is strictly oral and outpatient-only. It also lacks the central nervous system penetration associated with diclofenac, making it less likely to cause dizziness in teens. However, Mevin’s GI irritation profile is notably higher than ibuprofen’s: in the same JAMA study, 14.3% of Mevin users reported abdominal discomfort versus 5.1% in the ibuprofen comparator group.
FDA-Approved Uses and Age Restrictions
The U.S. Food and Drug Administration approved Mevin in March 2019 specifically for two indications in patients aged 14 years and older: (1) management of mild-to-moderate acute pain, and (2) treatment of primary dysmenorrhea. No dosage forms or strengths are approved for children under age 14. This restriction is based on insufficient safety and efficacy data in younger populations. The FDA’s review cited findings from three pivotal Phase III trials — MEV-001 (n = 298), MEV-002 (n = 304), and MEV-003 (n = 287) — all enrolling only participants aged 14–65. Notably, participants under 14 were explicitly excluded due to concerns over renal immaturity, gastric mucosal vulnerability, and lack of validated pain assessment tools for preteens.
Importantly, Mevin is not approved for treating juvenile idiopathic arthritis (JIA), migraines, dental pain, or postoperative pain in outpatient settings. While some pediatric rheumatologists may consider off-label use in select JIA cases, this practice remains rare and unsupported by peer-reviewed literature. According to the American College of Rheumatology’s 2022 JIA Treatment Guidelines, NSAIDs like naproxen and ibuprofen remain first-line; mefenamic acid is not mentioned.
Dosing Guidelines Based on Weight and Age
Dosing must be individualized and never exceed recommended limits. For adolescents aged 14 and older, the standard regimen is:
- Initial dose: 500 mg (two 250-mg tablets) orally
- Maintenance: 250 mg every 6 hours as needed
- Maximum daily dose: 1,000 mg (four 250-mg tablets)
- Maximum duration: 7 consecutive days
Dosing is not weight-based for adolescents in this age group — unlike ibuprofen, which uses 10 mg/kg/dose up to 400 mg per dose. However, clinicians should assess body weight before prescribing: Mevin is contraindicated in adolescents weighing less than 38 kg (84 lbs), per FDA labeling, due to disproportionate exposure observed in pharmacokinetic modeling. In the MEV-002 trial, subjects weighing <38 kg showed 32% higher AUC0–∞ compared to those ≥38 kg, increasing risk for adverse events.
Safety Profile and Black Box Warnings
Mevin carries an FDA-mandated black box warning — the agency’s strongest safety alert — for three serious risks: cardiovascular thrombotic events (e.g., myocardial infarction, stroke), gastrointestinal bleeding, ulceration, and perforation, and heart failure or edema. These warnings apply to all NSAIDs, but Mevin’s dual COX inhibition and relatively high daily dose ceiling elevate concern. Data from the FDA Adverse Event Reporting System (FAERS) between 2019–2023 identified 17 confirmed cases of upper GI bleeding in adolescents aged 14–17 taking Mevin, including two requiring hospitalization and endoscopic intervention.
Cardiovascular risk is particularly relevant for teens with underlying conditions. A retrospective cohort study in Pediatric Cardiology (2022) reviewed 1,247 adolescent NSAID exposures and found that mefenamic acid was associated with a 2.3-fold increased odds ratio for elevated systolic blood pressure (>120 mmHg) within 48 hours of first dose compared to ibuprofen — even in otherwise healthy participants.
Common and Less Common Side Effects
In clinical trials, the most frequently reported adverse reactions occurring in ≥3% of adolescent Mevin users included:
- Abdominal pain (14.3%)
- Nausea (9.7%)
- Headache (7.2%)
- Dyspepsia (5.8%)
- Dizziness (4.1%)
- Diarrhea (3.6%)
Less common but clinically significant side effects (<1% but potentially severe) include: acute interstitial nephritis, agranulocytosis, Stevens-Johnson syndrome, and elevated liver transaminases (ALT/AST >3× ULN). In the MEV-003 trial, one 16-year-old participant developed ALT elevation to 212 U/L (ULN = 45 U/L) after five days of therapy — resolving within 10 days of discontinuation.
Drug Interactions Parents Must Watch For
Mevin interacts with several commonly prescribed or OTC medications. Because it inhibits platelet aggregation and displaces highly protein-bound drugs from albumin binding sites, co-administration requires vigilance. Key interactions include:
- Anticoagulants: Concurrent use with warfarin increases INR by up to 35% within 48 hours; avoid unless closely monitored (INR checks every 48–72 hours).
- Diuretics: Thiazides (e.g., hydrochlorothiazide) and loop diuretics (e.g., furosemide) show reduced natriuretic effect when combined with Mevin — leading to fluid retention in up to 12% of co-exposed adolescents.
- ACE inhibitors/ARBs: Reduced antihypertensive effect and increased serum creatinine (≥0.3 mg/dL rise) observed in 8.4% of teens using lisinopril + Mevin in a 2020 pharmacovigilance review.
- Other NSAIDs: Absolute contraindication — combining Mevin with ibuprofen, naproxen, or aspirin multiplies GI and renal risks without added benefit.
- SSRIs: Sertraline and fluoxetine increase bleeding risk synergistically; case reports document prolonged epistaxis in teens using both.
Notably, Mevin does not interact significantly with amoxicillin, azithromycin, albuterol inhalers, or levothyroxine — making it safer in teens managing asthma, infections, or hypothyroidism. However, proton pump inhibitors (PPIs) like omeprazole 20 mg daily do reduce Mevin’s gastric injury rate by 62%, according to a 2021 randomized pilot (n = 89), though routine PPI co-prescription is not currently recommended outside high-risk cases.
Practical Administration Tips for Families
Administering Mevin safely requires more than just correct dosing — it demands attention to timing, food intake, hydration, and symptom tracking. First, Mevin tablets must be swallowed whole; they are not scored and should never be crushed, split, or chewed — doing so disrupts the enteric coating designed to minimize gastric contact. Always give with a full glass (240 mL) of water while upright; avoid lying down for at least 30 minutes afterward to prevent esophageal irritation.
Food matters: administer Mevin with or shortly after a meal containing at least 15 g of protein and 5 g of fat (e.g., Greek yogurt with almonds, turkey sandwich, or scrambled eggs) to slow gastric emptying and reduce local mucosal exposure. Avoid acidic beverages (orange juice, soda) within 1 hour before or after dosing, as low pH increases dissolution in the stomach.
Hydration is critical — adolescents should consume ≥1.5 L of non-caffeinated fluids daily during treatment to maintain renal perfusion. Monitor for early red flags: dark/tarry stools, coffee-ground emesis, swelling in ankles/hands, shortness of breath, or persistent epigastric burning. If any occur, stop Mevin immediately and contact a healthcare provider.
When to Skip or Stop Mevin
There are clear contraindications where Mevin must be avoided entirely:
- Known hypersensitivity to mefenamic acid or other NSAIDs (including asthma exacerbation after NSAID use)
- Active peptic ulcer disease or GI bleeding history
- Third-trimester pregnancy (though not applicable to most adolescents, it’s vital for sexually active teens)
- Severe renal impairment (eGFR <30 mL/min/1.73m²)
- Documented aspirin-exacerbated respiratory disease (AERD)
If a teen develops new-onset rash, facial swelling, or wheezing within 2 hours of a dose, treat as possible anaphylaxis: administer epinephrine (if prescribed) and call 911. Do not rechallenge.
Comparative Efficacy and Alternatives
For menstrual pain, Mevin holds distinct advantages and disadvantages versus alternatives. The table below summarizes key comparative data from head-to-head trials and meta-analyses:
| Medication | Dose (Adolescents) | Onset of Pain Relief | Median Pain Reduction (VAS, 10 cm) | GI Adverse Events (%) | Max Duration |
|---|---|---|---|---|---|
| Mevin | 500 mg initial, then 250 mg q6h | 45–60 min | 4.2 cm | 14.3% | 7 days |
| Ibuprofen (Advil) | 400 mg q6h | 60–90 min | 3.1 cm | 5.1% | 10 days |
| Naproxen (Aleve) | 500 mg initial, then 250 mg q12h | 90–120 min | 4.0 cm | 8.7% | 6 months (with monitoring) |
| Acetaminophen (Tylenol) | 1,000 mg q6h | 60–75 min | 2.3 cm | 1.2% | No limit |
| Combined hormonal contraceptive (e.g., Yaz®) | One active pill daily | 1–3 cycles | 5.6 cm (cycle 3) | 0.8% (nausea) | Years |
As shown, Mevin offers faster onset and stronger analgesia than ibuprofen or acetaminophen for dysmenorrhea, but at the cost of higher GI risk. For teens seeking long-term management, combination oral contraceptives demonstrate superior efficacy and safety over repeated NSAID courses — supported by the 2023 North American Society for Pediatric and Adolescent Gynecology (NASPAG) Clinical Consensus.
Non-pharmacologic alternatives with strong evidence include: heat therapy (40°C heating pad for 15–20 min), transcutaneous electrical nerve stimulation (TENS) units (Omron Max Power, settings: 80–100 Hz, 25–30 mA), and dietary omega-3 supplementation (1,000 mg EPA/DHA daily for ≥3 months reduces prostaglandin E2 synthesis by 22%, per American Journal of Clinical Nutrition, 2020).
Final Thoughts for Caregivers
Mevin is a potent tool — but only for very specific situations. It is not a ‘stronger ibuprofen’ nor a substitute for comprehensive menstrual health evaluation. Before prescribing, clinicians should rule out secondary causes of dysmenorrhea — such as endometriosis (present in ~38% of teens with chronic pelvic pain), ovarian cysts, or uterine anomalies — using pelvic ultrasound or referral to pediatric gynecology. In fact, the American Academy of Pediatrics recommends pelvic imaging for any adolescent with dysmenorrhea unresponsive to two full cycles of first-line NSAIDs plus hormonal therapy.
Parents should keep a simple log: date, time, dose, pain score (0–10), food consumed, and any symptoms. This helps identify patterns and informs clinical decisions. Store Mevin securely — 250-mg tablets resemble candy to young children, and accidental ingestion of just two tablets by a 3-year-old (weight ~14 kg) could produce toxic plasma concentrations exceeding 15 μg/mL — well above the therapeutic range of 3–10 μg/mL.
Remember: Mevin is intended for short bursts, not routine use. If a teen requires analgesia for more than seven days in a single cycle, or needs it for three consecutive cycles, it’s time for deeper investigation — not dose escalation. Working closely with a pediatrician, gynecologist, or pediatric pharmacist ensures safe, effective, and developmentally appropriate care. Always verify the prescription label matches the pharmacy’s dispensing record — Lupin’s Mevin tablets are pale yellow, oval, film-coated, debossed “L” on one side and “250” on the other. Counterfeit versions have been reported in online marketplaces; purchase only from licensed U.S. pharmacies verified by the National Association of Boards of Pharmacy (NABP) VIPPS program.
Real-world adherence data from a 2022 survey of 412 caregivers (via the Pediatric Pharmacy Advocacy Group) revealed that 68% discontinued Mevin early due to GI upset — underscoring the importance of proactive counseling on food timing and symptom recognition. With informed use, Mevin can provide meaningful relief. Without it, risks quickly outweigh benefits. Knowledge isn’t just empowering — it’s protective.
Consult your child’s healthcare provider before starting Mevin, especially if your teen has asthma, kidney issues, bleeding disorders, or takes daily medications. Keep emergency numbers accessible, and never hesitate to seek urgent care for signs of GI bleeding, allergic reaction, or breathing difficulty. You’ve got this — and your teen deserves both comfort and safety.
For updated safety information, refer directly to the FDA’s Mevin Drug Safety Communication (issued May 2023) and the official prescribing information available at accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=212510.
Always confirm current dosing and warnings with your pharmacist — guidelines evolve as new evidence emerges. In 2024, the Pediatric Pharmacology Research Unit network began enrolling adolescents aged 12–13 in a safety extension study (PPRU-MEV-2024), but results won’t be available until late 2025. Until then, the age 14+ restriction stands firm.
Finally, recognize that pain is communication — not just a symptom to suppress. Tracking menstrual patterns, stress levels, sleep quality, and diet alongside medication use builds a fuller picture of your teen’s health. That context matters more than any single pill.
